CA2180348A1 - Conjugues de medicaments a ciblage hepatocytaire - Google Patents

Conjugues de medicaments a ciblage hepatocytaire

Info

Publication number
CA2180348A1
CA2180348A1 CA002180348A CA2180348A CA2180348A1 CA 2180348 A1 CA2180348 A1 CA 2180348A1 CA 002180348 A CA002180348 A CA 002180348A CA 2180348 A CA2180348 A CA 2180348A CA 2180348 A1 CA2180348 A1 CA 2180348A1
Authority
CA
Canada
Prior art keywords
conjugate
crosslinker
ligand
covalently bonded
carrier molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002180348A
Other languages
English (en)
Inventor
Robert Plourde, Jr.
Ellen Carmichael
George L. Spitalny
Mark A. Findeis
Michael F. Ernst
Brett Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TargeTech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2180348A1 publication Critical patent/CA2180348A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Cette invention concerne des conjugués utilisés pour cibler un agent thérapeutique sur une cellule comprenant des récepteurs d'asialoglycoprotéine. Ces conjugués comprennent un agent thérapeutique et un ligand destiné au récepteur d'asialoglycoprotéine, ledit agent thérapeutique et ledit ligand étant liés par un agent de pontage. L'agent de pontage peut être un agent de réticulation, une molécule porteuse polyfonctionnelle ou un agent de réticulation et une molécule porteuse polyfonctionnelle. Dans une forme de réalisation préférée l'agent thérapeutique est un analogue nucléosidique ou de la colchicine et le ligand est de l'asialoorosomucoïde, de l'arabinogalactane ou un tri-(N-acétyle galactosamine aminohexyle glycoside) amide de tyrosyl(glutamyl)-glutamate. Les agents de réticulation préférés comprennent les dérivés d'aminoacyle, les dérivés de carboxyacyle, le phosphate, les peptides et les agents de réticulation labiles par réduction. Les molécules porteuses polyfonctionnelles comprennent les acides polyamino et les polysaccharides. On peut utiliser les conjugués de cette invention pour cibler un agent thérapeutique sur une cellule, par exemple pour inhiber la réplication d'ADN viral dans un hépatocyte infecté par un virus.
CA002180348A 1994-01-11 1995-01-11 Conjugues de medicaments a ciblage hepatocytaire Abandoned CA2180348A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18020794A 1994-01-11 1994-01-11
US08/180,207 1994-01-11
PCT/US1995/000448 WO1995018636A2 (fr) 1994-01-11 1995-01-11 Conjugues de medicaments a ciblage hepatocytaire

Publications (1)

Publication Number Publication Date
CA2180348A1 true CA2180348A1 (fr) 1995-07-13

Family

ID=22659615

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002180348A Abandoned CA2180348A1 (fr) 1994-01-11 1995-01-11 Conjugues de medicaments a ciblage hepatocytaire

Country Status (5)

Country Link
EP (1) EP0737077A1 (fr)
JP (1) JPH09510696A (fr)
AU (1) AU1679195A (fr)
CA (1) CA2180348A1 (fr)
WO (1) WO1995018636A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6296844B1 (en) 1995-09-27 2001-10-02 The General Hospital Corporation Asialocytokines and treatment of liver disease
US5981507A (en) * 1995-12-14 1999-11-09 Advanced Magnetics, Inc. Polymeric carriers linked to nucleotide analogues via a phosphoramide bond
JP5750209B2 (ja) * 2007-03-16 2015-07-15 アプタ バイオサイエンス リミテッド 機能性分子、機能性分子合成用アミダイド、及び標的物質解析方法
CA2786660A1 (fr) * 2010-01-14 2011-07-21 Glaxo Group Limited Molecules ciblant le foie
WO2012056976A1 (fr) * 2010-10-27 2012-05-03 公立大学法人横浜市立大学 Modulateur de l'activité de l'adénylate cyclase
CA3007058C (fr) 2015-12-03 2023-10-17 Biosight Ltd. Conjugues de cytarabine pour le traitement du cancer
JP2018535987A (ja) 2015-12-03 2018-12-06 バイオサイト リミテッド 癌療法のためのコンジュゲートの塩
CN108610384B (zh) * 2018-05-31 2022-02-22 沈阳药科大学 基于肠道mct1载体蛋白设计的前药及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2082507A1 (fr) * 1990-05-11 1991-11-12 George Y. Wu Protection ciblee contre les cytotoxines
US5656609A (en) * 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine

Also Published As

Publication number Publication date
EP0737077A1 (fr) 1996-10-16
WO1995018636A3 (fr) 1995-08-10
JPH09510696A (ja) 1997-10-28
WO1995018636A2 (fr) 1995-07-13
AU1679195A (en) 1995-08-01

Similar Documents

Publication Publication Date Title
US5981507A (en) Polymeric carriers linked to nucleotide analogues via a phosphoramide bond
Fujita et al. Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono-and polysaccharide derivatives.
ES2245805T3 (es) Polisacaridos que forman iminas, preparacion de los mismos y el uso de los mismos como adyuvantes de inmunoestimulantes.
Nishikawa et al. Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting
JP3814294B2 (ja) 親水性分子の脂質化のための方法および組成物
ES2225992T3 (es) Nuevos complejos polimericos para la transfeccion de acidos nucleicos, con residuos que desestabilizan unas membranas celulares.
US20160015823A1 (en) Peptide-dendrimer conjugates and uses thereof
US20060127310A1 (en) Amplification of biotin-mediated targeting
AU4094300A (en) Amplification of folate-mediated targeting to tumor cells using polymers
CA2566195A1 (fr) Procede de preparation de conjugues doxorubicine-albumine humaine lactosaminee
CA2376175A1 (fr) Vitamine pour therapie a double ciblage
US20120213732A1 (en) Targeted delivery of antiviral compounds through hemoglobin bioconjugates
CA2180348A1 (fr) Conjugues de medicaments a ciblage hepatocytaire
Seymour Soluble polymers for lectin-mediated drug targeting
Fiume et al. Targeting of antiviral drugs to the liver using glycoprotein carriers
Di Stefano et al. Selective delivery to the liver of antiviral nucleoside analogs coupled to a high molecular mass lactosaminated poly-L-lysine and administered to mice by intramuscular route
EP1279405A1 (fr) Medicaments a long temps de conservation dans un tissu
EP0234151B1 (fr) Glycoprotéines modifiées par oxydation et formation de base de Schiff, inhibant les ribosomes, procédé d'obtention et immunotoxines comprenant une telle glycoprotéine
Fiume et al. Targeting of antiviral drugs by coupling with protein carriers
US5959077A (en) Hepatotropic conjugates of antiviral drugs carriers thereof and pharmaceutical compositions containing them
US6291638B1 (en) Hepatotropic conjugates of antiviral drugs carriers thereof and pharmaceutical compositions containing them
Hoes et al. Design of soluble conjugates of biodegradable polymeric carriers and adriamycin
CA2566874C (fr) Administration ciblee de composes antiviraux au moyen de bioconjugues a base d'hemoglobine
Fiume et al. Hepatocyte targeting of antiviral drugs coupled to galactosyl-terminating glycoproteins
EP0652776B1 (fr) Conjugues hepatotropes de medicaments antiviraux, vehicules pour ces conjugues et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead